Abstract
P522 Aims: To evaluate the impact of Campath-1H induction in adult liver allo-transplantation. Methods: Campath-1H induction and low dose Tacrolimus monotherapy was administered Between December 2001 and March 2004, to 77 patients, recipients of cadaveric liver allografts. Fifty other patients that received their liver graft during the same period of time under our standard Tacrolimus/steroids protocol served as the control group. Patients with Hepatits C, malignancies, unconventional transplant procedures or recipients of additional organs (kidney) were not included in the study. The two groups were comparable for patient’s characteristics and primary disease. Clinically suspected and biopsy proven mild rejections were treated with a short course of steroids. Moderate or severe rejections were treated additionally with OKT3. Results: In the C-1H group, 3 patients lost their graft due to primary non-function, recurrent hepatitis and chronic rejection and had to be re-transplanted. There were 3 deaths, one soon after the transplant procedure from a perioperative stroke, and the other two at 4 and 5 months post-transplantation due to pneumonia-sepsis, and PTLD. Patient and graft survival were similar in the two groups. The incidence of acute rejection was significantly lower the first 3 months post transplantation and slightly lower in the C1H group during a 12 month follow up (47% vs 57%). During a 12 month follow up, the mean Tacrolimus dose, 12-hour trough level, percentage of patients on maintenance steroids, creatinine levels, and incidence of conversion to other immunosupressive agents for nephrotoxicity were significantly lower in the C1H group (P<.05). Immunosuppression related complications in the study group included Herpes Zoster (n=7), Kaposi sarcoma (n=1) and skin cancer (n=1) and in the control group EBV enteritis(n=1) and skin cancer(n=1). Conclusions: Campath-1H induction and low dose Tacrolimus monotherapy is an effective regimen in liver transplantation with less renal toxicity and less use of maintenance steroids.FigureFigure
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
